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A B S T R A C T
Osteogenesis imperfecta is a hereditary bone dysplasia characterized by bone fragility, de-
formity, and short stature. Treatment focuses on preventing bone fractures and
symptom relief. Pamidronate, a second-generation bisphosphonate drug that minimizes bone
loss, is the chosen treatment in osteogenesis imperfecta. Radiologically, each
cycle of pamidronate treatment is depicted as a line of sclerosed nondecalcified
cartilage at the metaphysis, termed a pamidronate line. In this case report, we demon-
strate that a treatment timeline can be visualized on plain radiographs as the number
and spacing of pamidronate lines reflects the number and timing of treatment cycles.
The educational value of this is to reassure physicians of the benign nature of “zebra lines,”
to demonstrate that the pamidronate lines migrate and fade with bone growth, and alert
physicians that the lack of expected pamidronate lines during treatment may reflect a change
in the patient’s condition that reduces the effectiveness of bisphosphonate infusions.
© 2017 the Authors. Published by Elsevier Inc. under copyright license from the University
ofWashington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Osteogenesis imperfecta (OI) is a skeletal dysplasia character-
ized by fractures due to bone fragility, with variable features
of blue sclera, bone deformity, short stature, ligamentous
laxity, and dental abnormalities (dentinogenesis imperfecta)
[1]. Mutations in the alpha 1 and alpha 2 chains of Collagen
Type 1 (COL1A1 and COL1A2) account for 80%-90% cases but
with intriguing heterogeneity. The original 1979 Sillence OI
classification system remains useful [2]. Recent nomencla-
ture revision occurred to reflect the complexity of now 19
different genes implicated in OI [3]. Nevertheless, it largely
retains categorization according to clinical severity with Type
1 the mildest form, Type 3 severely progressively deforming,
and Type 2 lethal. Multidisciplinary team management of
patients with OI has significantly developed over recent
years, encompassing bone strengthening medical treat-
ments, orthopedic interventions, and comprehensive therapy
inputs. Management focuses on reducing fractures, limb
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deformity, and pain, with the aim of improving patient’s
quality of life.
Bisphosphonates are the mainmedical treatment in OI, with
intravenous pamidronate, a second-generation bisphosphonate,
the most widely used approach [4]. Pamidronate is adminis-
tered as regular infusions over several years to increase bone
mineral density and reduce fractures. At a cellular level,
pamidronate reduces osteoclast activity which minimizes bone
loss. Each pamidronate infusion interrupts the active osteo-
blast front within the growth plate from decalcifying the growth
plate cartilage during cell turnover [5]. These rows of scle-
rosed nondecalcified cartilage present as lines of cartilage
calcification persisting frommetaphysis into diaphysis, termed
pamidronate lines. In a child’s growing skeleton, bone growth
takes each pamidronate line up into the diaphysis, and each
round of treatment brings a new pamidronate line.These par-
allel lines progressively result in a “zebra line appearance.”The
number and spacing of pamidronate lines reflects the number
and timing of treatments, much like tree-rings reflect the age
of a tree as well as the amount of growth in a year.With time,
they disappear as the calcified cartilage moves from the me-
taphysis into the diaphysis, and they are gradually converted
into bone [5,6]. The pamidronate lines are not correlated with
worsening pathology in children with OI; they are a radiologi-
cal finding that reflects the effective administration of the
bisphosphonate infusion and should not be the cause of alarm
in physicians.
Case report
This 9.5-year-old Caucasian boy was noted at birth to have po-
sitional talipes equinovarus, joint laxity, large anterior fontanelle,
and blue sclerae.The patient experienced his first low trauma
fracture of right tibial shaft fracture when he was 6 months
old, with minimal handling. Family history indicated a large
pedigree with many affected members with osteogenesis
imperfecta type 1 with an inheritance pattern consistent with
the expected autosomal dominant nature of Type 1 OI. By the
age of 6-10 months, the patient had 7 fractures due to minimal
trauma. The fractures were mainly of the lower limb bones,
specifically the tibia, fibula, andmetatarsals.Two fractures were
found in larger bones such as the femur and pelvis. Physical
examination at birth revealed features supportive of a diag-
nosis of OI. Clinical features during childhood were similarly
consistent: hypermobility, pes planus, andmild lumbar scoliosis.
Radiological evidence showed features of OI, such as the
presence of Wormian bones on lateral skull radiographs.
However, radiographs do not provide an accurate assessment
of bone density. Bone densitometry was assessed using dual-
energy X-ray absorptiometry. At aged 3.6 years it showed total
body bone mineral density z-score +0.7 SDS and lumbar (L1-
L4) bone mineral density z-score +1.4 SDS. These values are
within the normal range, which can occur in OI. Dual-energy
X-ray absorptiometry is a proxy marker for bone strength, al-
though the collagen abnormality present in OI affects bone
quality and strength and not always density. Genetic studies
indicated that the patient had the same mutation as other af-
fected family members and was heterozygous for c.3584G>A,
p.C1195Y mutation within the COL1A1 gene.
The diagnosis of OI Type 1 is largely made on clinical
grounds. The patient’s clinical history and examination were
indicative of OI. Genetic studies are not a prerequisite for the
diagnosis of Type OI, although they are increasingly undertak-
en in today’s practice. Genetic studies cannot predict clinical
severity in fracture frequency.There is significant clinical het-
erogeneity even within individuals affected with the same
mutation in 1 kindred, as was the case in this pedigree.
Bisphosphonate therapy is not used prophylactically in pedi-
atric OI, but this patient’s frequent fragility fractures in infancy
crossed the threshold to recommend bisphosphonate therapy
which is now a well-accepted form of treatment [7].
The patient commenced a standard course of pamidronate
infusions. The patient’s radiographs provide a visual story of
his pamidronate treatment (Fig. 1). Over 3 years, the patient
received 8 cycles (1 mg/kg/day for 3 consecutive days) of
pamidronate. Treatment was interrupted for 3 years due to
severe procedural anxiety around cannulation, giving
“pamidronate-free” bone formation over that period.The patient
Fig. 1 – Radiograph of the left knee taken aged 7.25 years.
Black arrows indicate 8 dense parallel pamidronate lines in
the distal femoral and proximal tibial diaphysis, each
corresponding to a treatment cycle (numbered from oldest
to most recent). The ensuing 3-year treatment
discontinuation corresponds to the lower density bone
(broken 2-headed arrow). This radiograph was taken 6
months after recommencing pamidronate infusions and
re-institution (white arrow).
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then restarted treatment and over the next 4 years, received
7 cycles (4 cycles of 1 mg/kg/day for 3 days then 3 cycles of
1 mg/kg/day for 2 days) (Fig. 2).
Discussion
We chose to present this care report because of the unusual pre-
sentation of pamidronate lines in a growing skeleton and the
educational value in raising awareness among physicians on the
management of OI and the effect of bisphosphonate infusions
on the pediatric skeleton.
Pamidronate “zebra” lines are a pediatric phenomenon ap-
pearing in the growing skeleton. Radiologists, orthopedists, or
emergency department practitioners whomore commonly view
adult radiographs may be alarmed by their unexpected ap-
pearance in a radiograph taken for a different indication.This
can lead to various inappropriate differential diagnoses such
as underlying bone disease, nutritional abnormalities, or frac-
tures. This brings undue anxiety on the part of the clinician,
the child, and family, potentially with unnecessary addition-
al investigations.This report serves as an important educational
message to physicians of the benign nature of this radiologi-
cal feature, as the rarity of this condition makes it unlikely that
they would have to have a large number of children with OI
in their patient cohort.
This radiological appearance of pamidronate lines has been
studied histomorphometrically and a persisting calcified ridge
correlates with the sclerosed lines on plain radiograph [8].
Reports also indicate that the lines fade with time [9], indi-
cating that eventually osteoclast activity and bone turnover
result in decalcification of those lines. This picture is aptly
demonstrated by this case (Fig. 2). This case also demon-
strates that the lines are not always parallel at uniform
distances, as the gap between them reflects the timing of
treatment. This case shows an unusual appearance with a
relatively long gap in treatment of 3 years. This highlights
that exploration of treatment history should be taken into
account when interpreting a child’s radiographs and further
reassure physicians of the benign nature of the pamidronate
lines.
It is important to note that pamidronate lines do not
solely occur in childhood OI, as bisphosphonates are also
used judiciously in other pediatric chronic conditions com-
plicated by low bone mass with fragility fractures such as
Duchenne muscular dystrophy or cerebral palsy and also
chronic recurrent multifocal osteomyelitis [10]. Hence it can
be expected that those patients will also exhibit similar ra-
diological findings. Moreover, this illustrative case also provides
useful learning points to clinicians treating children with a
variety of medical conditions, where interruptions in
bisphosphonate therapy can result due to other events occur-
ring due to their underlying medical condition and can also
be used as a monitoring method for the effectiveness of
bisphosphonate infusions.
Finally, medical treatments are changing; now the more
potent bisphosphonate zoledronic acid is becoming the pre-
ferred agent in the management of OI.This more potent agent
is also administered by intravenous infusion but less often, gen-
erally 6 monthly in the growing skeleton. To the present day
the appearance of “Zol-Zebra lines” has not been reported. It
is possible that they could have a similar or more intense ap-
pearance and be further apart that pamidronate lines as
zoledronic acid is administered in a much higher concentra-
tion and with a longer treatment interval. This is something
to continue observing. Correlation of clinical and medication
history will remain important.
In conclusion, pamidronate lines are a radiological finding
representing areas of sclerosed nondecalcified cartilage at the
metaphysis, in pediatric patients treated with bisphosphonate
infusions for conditions that compromise their skeletal integ-
rity.Although an unusual radiological feature, physicians should
be reassured of their benign nature. As shown in this case
report, their number and distance indicate the timing of
pamidronate infusion cycles reflecting the treatment timeline.
As the bone grows they are fully absorbed.With bisphosphonate
infusions being increasingly used in OI and other conditions
with skeletal compromise, this is likely to be a more common
Fig. 2 – Radiograph of the left knee taken aged 9.5 years,
2.6 years into the “second phase” of pamidronate
infusions. The 7 infusion cycles during this period
correspond to pamidronate lines in the distal femoral,
proximal tibial, and fibular metaphyses and diaphyses
(black arrows numbered from oldest to most recent).
Remnants of the old pamidronate lines from treatment
3 years previously are fading into the diaphysis as they are
gradually converted into bone (rectangle).
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presentation. It is important that this is correctly identified by
treating physicians to prevent undue anxiety on the part of the
clinician, the child, and family, potentially with unnecessary
additional investigations.
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